Open in interactive viewer → charts, metric popovers & call review

DiaSorin's 8% Quarter Is Real; the 34% Margin Is Half a Refund

LIAISON PLEX finally accelerates, McKesson de-risks NES, and a quiet LTG upgrade hides a decelerating US immuno franchise
DIA.MI · Earnings Call · 2026-11-12

The 8% Is Real. The 34% Is Two-Thirds Real.

DiaSorin's Q3 2026 is the first print in several quarters where the top line, not the excuse list, did the talking. Revenue of EUR 308 million grew 8% at constant exchange rate, an acceleration from a first nine months that managed only 3% CER (EUR 910 million) after a EUR 15 million FX headwind and a first half spent apologising for destocking and China. “At constant exchange rate, the company delivered a growth of 8%, which is an acceleration compared to the previous quarters” — Carlo Rosa, Chief Executive Officer · 2026-11-12, Carlo Rosa opened — and for once the phrasing survives contact with the numbers. What the quarter is not is a margin breakthrough. Adjusted EBITDA of EUR 103 million at a 34% CER margin, up 15% year-on-year, was flattered by a tariff refund that has been the slowest-moving receivable in diagnostics.

This result is benefiting from both our stronger revenues, the operating leverage potential of our business, as well as from a refund of approximately EUR 5 million of IEEPA tariffs, which contributed roughly 1.5 points of margin. So if you make the calculation excluding the refund, the Q3 EBITDA margin at constant exchange rate would have still been between 32% to 33%.

Alberto Donati, Chief Financial Officer · 2026-11-12
So the clean read is 32-33%, exactly the reiterated full-year guidance band, on revenue growth of 5-6% CER. The tariff refund theme is the one recurring item the company would rather stop discussing: on the July call the CFO had booked roughly $2.5 million and warned there was no visibility on the rest, “it could be in H2, it could be in 2027” — Alberto Donati, Chief Financial Officer · 2026-07-31. It landed in H2. That is timing, not operating leverage — and it is the difference between a beat and a meet.

Multiplexing: the one genuinely new number on the page

The strategic centre of gravity has moved to LIAISON PLEX and VERIGENE, where the automated business grew 36% in the quarter. Customers moved from 150 to over 170, GI launched in July in North America, and — the detail worth stealing — 65% of new contracts now sign on the flexible configuration versus fixed. Rosa's explanation of why the ramp is finally happening is the most interesting causal chain in the transcript: payer behaviour, not product superiority, is doing the pushing. “The denial rate from payers of complex panels is becoming — is getting higher... this fundamentally puts a lot of pressure on the complex panels and is helping us out to get to these institutions with a solution that makes clinical sense” — Carlo Rosa, Chief Executive Officer · 2026-11-12. That is the complex panels thesis maturing from a management slide into a reimbursement reality, and it is a genuine company-unique signal rather than sector boilerplate. The disclosure style also shifted: Rosa now quotes run-rates — LIAISON MDX "roughly EUR 100 million in annualized revenues", multiplexing franchise another EUR 100 million, targeted specialty EUR 45 million — which is why annualized revenues ranks third in this quarter's keyword set. That is capital-markets-day language, not earnings-call language.

The NES silence is strategic, but the channel news is not

DiaSorin again refused to give LIAISON NES placement numbers — the third consecutive quarter of that refusal, so analysts should stop asking. July's version was “I'm not going to give you numbers. It's too early” — Carlo Rosa, Chief Executive Officer · 2026-07-31; November's is a promise to comment at the end of the season. What did change is the risk framing. Rosa has spent quarters describing the point-of-care platform as well engineered and the distribution as the unknown; today the unknown is resolved enough to talk about shape. “McKesson has been doing a fantastic job for us, and we now see that we have penetration in several large portions of the country” — Carlo Rosa, Chief Executive Officer · 2026-11-12 — with roughly 40% of placements replacing antigen accounts, a conversion the antigen keyword has flagged as a theme since 2021. The McKesson channel de-risking is the single most under-priced sentence in the release, and it sits inside a broader point-of-care bid: the global tape shows point of care among the better 90-day advancers, with Thermo Fisher, Danaher, IDEXX, Bio-Rad and Haemonetics in the cohort.

What management stopped bragging about

Two quiet edits matter more than anything said loudly. First, North America immunodiagnostics grew 5% — against a franchise that has compounded double digits for years. The cause is a TB-heavy commercial-lab book and its ordering pattern, the same vocabulary used on the July call, now guided down to high-single-digit as the structural trajectory rather than a blip. The company's own keyword set puts commercial lab second and ordering pattern fourth this quarter — the market's questions have migrated from growth to volatility. Europe's 8% and the TB assay's >20% (with over 80% of the base converted to the high-throughput kit) are the offset, but Roche has still not shown up: “so far we have not seen Roche on the market... I don't know of a single customer that has a Roche product” — Carlo Rosa, Chief Executive Officer · 2026-11-12. The Roche keyword spiked to its highest momentum on record this quarter, and the answer was: not yet. Second, and almost buried, licensed technology was upgraded mid-year. July's slide deck guided LTG to low single digits and analysts pushed back on the mismatch — “I see in the slide deck you guys have low single-digit growth as the guide for the full year, but all of the commentary seems to be pointing to the possibility of mid- to high single digits” — Anna Ractliffe, Analyst · 2026-07-31. It is now officially mid- to high single digit, on a life-science funding recovery the CFO was careful to size down: LTG is small enough that 1-2 points does not move group guidance. The Life Science recovery is real; it is also not load-bearing.

The January cliff, and the inventory bet

Three things sit outside the quarter's control. PAMA returns in January with, per Rosa, a coin-flip on whether Congress defers again — the same structural worry he has voiced since November 2025, when he argued the portfolio's Medicare exposure was structurally lower than in 2015 because the US business had rotated from vitamin D into specialty testing. China's reagent business is still shrinking, minus 12% versus minus 24% prior quarters, with the improvement coming from instrument sell-in rather than any VBP in China relief. And a respiratory season that has not started: targeted respiratory is running about -30%, and the full-year guide is built on a season "broadly in line with last year's" plus incremental NES. respiratory season is the swing factor for the entire Q4, and it is a weather variable wearing a P&L. Meanwhile the balance sheet is being leaned into the launch. Net debt of EUR 782 million, up EUR 200 million from year-end, reflects a deliberate NES inventory build — “the inventory increase is totally linked with building up NES inventory, both systems as well as starting also with the reagents” — Alberto Donati, Chief Financial Officer · 2026-11-12 — plus a completed buyback of 3.79 million shares, 6.78% of capital, for roughly EUR 250 million, and EUR 65 million of dividends. Free cash flow of EUR 127 million covered less than half of that. The verdict: this is a company whose growth engine has genuinely restarted in molecular and whose profit line is being propped by a one-off refund and a seasonal bet. The tell is that tax rate — a housekeeping item — was the single highest-momentum keyword in DiaSorin's own Q3 set. When the most-discussed number on the call is the tax line, the narrative is between chapters.